Literature DB >> 18555914

Tobacco addiction.

Dorothy K Hatsukami1, Lindsay F Stead, Prakash C Gupta.   

Abstract

Tobacco use is associated with 5 million deaths per year worldwide and is regarded as one of the leading causes of premature death. Comprehensive programmes for tobacco control can substantially reduce the frequency of tobacco use. An important component of a comprehensive programme is the provision of treatment for tobacco addiction. Treatment involves targeting several aspects of addiction including the underlying neurobiology and behavioural processes. Furthermore, building an infrastructure in health systems that encourages and helps with cessation, as well as expansion of the accessibility of treatments, is necessary. Although pharmacological and behavioural treatments are effective in improving cessation success, the rate of relapse to smoking remains high, emphasising the strong addictive nature of nicotine. The future of treatment resides in improvement in patient matching to treatment, combination or novel drugs, and viewing nicotine addiction as a chronic disorder that might need long-term treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555914      PMCID: PMC4732578          DOI: 10.1016/S0140-6736(08)60871-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  131 in total

1.  Tobacco-dependence medications: public health and regulatory issues.

Authors:  J E Henningfield; J Slade
Journal:  Food Drug Law J       Date:  1998       Impact factor: 0.619

Review 2.  Does smoking reduction increase future cessation and decrease disease risk? A qualitative review.

Authors:  John R Hughes; Matthew J Carpenter
Journal:  Nicotine Tob Res       Date:  2006-12       Impact factor: 4.244

3.  Craving is associated with smoking relapse: findings from three prospective studies.

Authors:  J D Killen; S P Fortmann
Journal:  Exp Clin Psychopharmacol       Date:  1997-05       Impact factor: 3.157

4.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

5.  Long-term potentiation of excitatory inputs to brain reward areas by nicotine.

Authors:  H D Mansvelder; D S McGehee
Journal:  Neuron       Date:  2000-08       Impact factor: 17.173

6.  Mood disturbance fails to resolve across 31 days of cigarette abstinence in women.

Authors:  David G Gilbert; F Joseph McClernon; Norka E Rabinovich; Louisette C Plath; Carmen L Masson; Allison E Anderson; Kaye F Sly
Journal:  J Consult Clin Psychol       Date:  2002-02

7.  Smoking cessation guidelines for health professionals: an update. Health Education Authority.

Authors:  R West; A McNeill; M Raw
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

Review 8.  The genetic epidemiology of smoking.

Authors:  P F Sullivan; K S Kendler
Journal:  Nicotine Tob Res       Date:  1999       Impact factor: 4.244

9.  Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study.

Authors:  N S Godtfredsen; M Osler; J Vestbo; I Andersen; E Prescott
Journal:  J Epidemiol Community Health       Date:  2003-06       Impact factor: 3.710

10.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more
  72 in total

1.  Effects of economy type and nicotine on the essential value of food in rats.

Authors:  Rachel N Cassidy; Jesse Dallery
Journal:  J Exp Anal Behav       Date:  2012-03       Impact factor: 2.468

2.  Smoking cessation counseling in Qatar: community pharmacists' attitudes, role perceptions and practices.

Authors:  Maguy Saffouh El Hajj; Reem Raad Al Nakeeb; Raja'a Ali Al-Qudah
Journal:  Int J Clin Pharm       Date:  2012-06-26

3.  Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Catalina Lopez-Quintero; Deborah S Hasin; José Pérez de Los Cobos; Abigail Pines; Shuai Wang; Bridget F Grant; Carlos Blanco
Journal:  Addiction       Date:  2010-11-16       Impact factor: 6.526

4.  Do counselor techniques predict quitting during smoking cessation treatment? A component analysis of telephone-delivered Acceptance and Commitment Therapy.

Authors:  Roger Vilardaga; Jaimee L Heffner; Laina D Mercer; Jonathan B Bricker
Journal:  Behav Res Ther       Date:  2014-08-07

Review 5.  Secondary prevention in the intensive care unit: does intensive care unit admission represent a "teachable moment?".

Authors:  Brendan J Clark; Marc Moss
Journal:  Crit Care Med       Date:  2011-06       Impact factor: 7.598

6.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

7.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

Review 8.  New insights into the genetics of addiction.

Authors:  Ming D Li; Margit Burmeister
Journal:  Nat Rev Genet       Date:  2009-04       Impact factor: 53.242

Review 9.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

Review 10.  A testable prognostic model of nicotine dependence.

Authors:  Rachel Badovinac Ramoni; Nancy L Saccone; Dorothy K Hatsukami; Laura J Bierut; Marco F Ramoni
Journal:  J Neurogenet       Date:  2009-01-31       Impact factor: 1.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.